Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals (VRTX) - Get Report  predicts sales of the cystic fibrosis drug Orkambi in the range of $1.1 billion to $1.3 billion, which is lower than initially expected. The Orkambi guidance also reflects uncertainty over the timing of European reimbursements.

This article was written by a staff member of TheStreet.